UNSPSC 51171979: Sacrosidase

This classification denotes a glycoside hydrolase found primarily in plants and yeasts, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A7F670F2Y, chemically known as .beta.-fructofuranosidase but generally known as Sacrosidase. European Medicines Agency schedules Sacrosidase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB38353. World Health Organization schedules bismuth subcitrate in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, SACROSIDASE remains the US FDA Preferred Term for this commodity.

UNSPSC 51171979 Sacrosidase, a Commodity code, encompasses enzyme-based pharmaceutical products used in state and local health, criminal justice, and benefit administration settings. Recent solicitations show sacrosidase and related pharmaceutical products being procured through multiple channels — direct to individual jurisdictions for specialized testing and treatment programs, through cooperative purchasing alliances serving multi-state networks of public health and correctional facilities, and as part of broader pharmacy benefit management initiatives. The issuing bodies include county criminal justice departments, state health and human services agencies, and cooperative purchasing organizations representing state and local government members across multiple jurisdictions. Work under this code ranges from specialized pharmaceutical supply agreements with cGMP and DSCSA compliance requirements to direct-to-manufacturer prescription fulfillment models designed to bypass traditional pharmacy benefit manager intermediaries.

Recent activity spans Texas and Minnesota, with the most concrete near-term opportunity in Collin County, Texas. Collin County's Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services valued at approximately $600,000 over two years (three optional one-year renewals), which includes immunoassay screening and confirmation testing requiring SAMHSA or state lab certification. The Minnesota Department of Administration issued RFP S1070000015802 through the Multistate Cooperative Purchasing Alliance (MMCAP) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local facilities in Minnesota and Oregon, requiring cGMP certification, DSCSA compliance, and a 3 percent administrative fee structure. The Texas Health and Human Services Commission posted exploratory RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for self-insured state employee health plans, signaling future formal procurement activity outside traditional PBM arrangements.